Hemodialysis requirement after the first dose of durvalumab following chemoradiation therapy: a case report

Anticancer Drugs. 2024 Feb 1;35(2):199-202. doi: 10.1097/CAD.0000000000001544. Epub 2023 Nov 11.

Abstract

Durvalumab is the first immune check point inhibitor that was approved for use following concurrent platinum-based chemoradiation, in patients with unresectable stage III non-small cell lung cancer. The new treatment regimen of durvalumab administered after chemoradiation resulted in higher response rates and required careful immune-related adverse effects management. We experienced a rare case of severe acute kidney injury (AKI) requiring hemodialysis after only the first dose of durvalumab, in a patient who was diagnosed with immune-related AKI by renal biopsy. Although severe (Grade 3 or more) immune-related AKI occurred in 0.9% of patients treated with durvalumab, some drugs and radiation may increase immune-related AKI. Further research is needed to identify the clinical characteristics of patients who tend to develop severe AKI so as to prevent it, by reviewing such rare cases as ours.

Publication types

  • Case Reports

MeSH terms

  • Acute Kidney Injury*
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Chemoradiotherapy / adverse effects
  • Humans
  • Lung Neoplasms* / drug therapy
  • Renal Dialysis

Substances

  • durvalumab